49 completed, 5 unknown, 4 recruiting, 1 active not recruiting. 61 Phase 1, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 61 | Completed 49, Unknown 5, Recruiting 4, Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 14 | Completed 13, Recruiting 1 |
Follow Pneumococcal Infections: new trials by email Literature Review of Pneumococcal Infections trials Research Report on Pneumococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M), PCV24 vaccine (dose H), PCV24 vaccine (dose M) - Streptococcus Pneumoniae Infection | Phase 1 / Phase 2 | Recruiting | CanSino Biologics Inc. | 854 | 2026-05-24 | 2026-08-05 |
| A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) V118C (Stage 1), V118C (Stage 2), PCV20 (Stage 1) - Pneumococcal Infection | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 210 | 2026-01-13 | 2026-10-02 |
| Serum Collection Study for Assay Development Gamma-PN - Pneumococcal Disease, Invasive, Pneumococcal Disease | Phase 1 | Recruiting | GPN Vaccines | 12 | 2025-10-01 | 2025-10-03 |
| A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults 20vPnC, 13vPnC - Pneumococcal Disease | Phase 1 | Completed | Pfizer | 400 | 2025-07-06 | 2026-02-25 |
| Clinical Trial of PCV24 in Adults Aged ≥18 Years Sinovac Low-dosage PCV24, Sinovac Middle-dosage PCV24, Sinovac High-dosage PCV24 - Pneumococcal Infectious Disease | Phase 1 / Phase 2 | Completed | Sinovac Life Sciences Co., Ltd. | 385 | 2025-06-18 | 2026-04-21 |
| A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant 20vPnC, 13vPnC - Pneumococcal Disease | Phase 1 | Active not recruiting | Pfizer | 200 | 2025-06-15 | 2026-10-23 |
| A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60 26-valent Pneumococcal Conjugate Vaccine, 13-valent Pneumococcal Conjugate Vaccine - Pneumococcal Diseases | Phase 1 | Not yet recruiting | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 60 | 2025-05-27 | 2025-05-18 |
| Clinical Trial of PCV24 in Infants Aged 2-23 Months Sinovac PCV24, Prevnar® - Pneumococcal Infectious Disease | Phase 1 | Recruiting | Sinovac Life Sciences Co., Ltd. | 180 | 2025-05-08 | 2026-01-28 |
| Clinical Trial of PCV24 in Children Aged 2-17 Years Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Prevenar13® - Pneumococcal Infectious Disease | Phase 1 | Completed | Sinovac Life Sciences Co., Ltd. | 119 | 2024-09-07 | 2026-01-28 |
| Study of Gamma PN3 in the Elderly Gamma PN3, Prevnar - Pneumonia, Pneumococcal | Phase 1 | Completed | GPN Vaccines | 105 | 2024-08-26 | 2025-05-11 |
| Clinical Trial of PCV24 in Adults Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Pneumovax® - Pneumococcal Infectious Disease | Phase 1 | Completed | Sinovac Life Sciences Co., Ltd. | 170 | 2024-06-21 | 2025-04-16 |
| Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years PCV24 formulation 1, PCV24 formulation 2, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine - Pneumococcal Infectious Disease | Phase 1 | Completed | Reinovax Biologics Co., LTD | 230 | 2024-04-27 | 2026-08-17 |
| A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Sinovac PCV13, PREVNAR 13 - Pneumococcal Infectious Disease | Phase 1 | Completed | Sinovac Research and Development Co., Ltd. | 140 | 2024-01-04 | 2026-01-28 |
| A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease | Phase 1 / Phase 2 | Completed | Pfizer | 1710 | 2023-12-20 | 2026-09-25 |
| Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, PPSV23 - Pneumococcal Infectious Disease | Phase 1 | Completed | Reinovax Biologics Co., LTD | 240 | 2023-11-19 | 2024-11-07 |
| A Phase I Study of XJ103 in Chinese Healthy Subjects XJ103 Injection, Placebo - Pneumococcal Disease | Phase 1 | Unknown | Starmab biologics（Shanghai）Co,.ltd | 38 | 2023-09-12 | 2024-03-27 |
| Extension Safety and Immunogenicity Study of GPNV-001 Gamma-PN3, Pneumovax-23, Prevenar-13 - Pneumococcal Infections | Phase 1 / Phase 2 | Completed | GPN Vaccines | 60 | 2023-07-17 | 2024-12-18 |
| A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control - Pneumococcal Disease | Phase 1 | Completed | Pfizer | 90 | 2023-04-19 | 2024-07-29 |
| A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine MVX01, MVX01 Placebo - Pneumococcal Vaccine | Phase 1 | Unknown | Matrivax Research and Development Corporation | 75 | 2023-03-07 | 2024-03-29 |
| Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3. Gamma-PN3, Prevenar-13, Pneumovax-23 - Pneumococcal Infections | Phase 1 | Completed | GPN Vaccines | 118 | 2023-01-16 | 2024-09-05 |
Showing 20 of 61. Sign in to see all of them.
Pneumonia, Pneumococcal (10) · Pneumonia (5) · Pneumonia, Bacterial (3) · HIV Infections (2) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1) · Bacterial Infections (1) · Healthcare-Associated Pneumonia (1) · Streptococcal Infections (1)
Bacterial Infections and Mycoses (61) · Gram-Positive Bacterial Infections (61) · Infections (61) · Bacterial Infections (60) · Streptococcal Infections (60) · Lung Diseases (16) · Respiratory Tract Diseases (16) · Respiratory Tract Infections (16) · Pneumonia (11) · Pneumonia, Bacterial (9) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2) · Immune System Diseases (2)
13-valent pneumococcal vaccine (15) · Heptavalent Pneumococcal Conjugate Vaccine (9) · 23-valent pneumococcal capsular polysaccharide vaccine (8) · Pneumococcal Vaccines (8) · Sodium Chloride (2) · Tetanus Toxoid (2) · Vaccines, Combined (2) · 10-valent pneumococcal conjugate vaccine (1) · CRM197 (non-toxic variant of diphtheria toxin) (1) · PHiD-CV vaccine (1) · Pentavac (1) · Protons (1) · Referral and Consultation (1) · colistinmethanesulfonic acid (1)
Pfizer (8) · Merck Sharp & Dohme LLC (7) · Sinovac Life Sciences Co., Ltd. (5) · GPN Vaccines (4) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (2) · CanSino Biologics Inc. (2) · Centers for Disease Control and Prevention (2) · GlaxoSmithKline (2) · PATH (2) · Reinovax Biologics Co., LTD (2) · Sanofi (2) · Sanofi Pasteur, a Sanofi Company (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Affinivax, Inc. (1)
United States (17) · China (16) · Australia (5) · Switzerland (3) · Bangladesh (2) · Belgium (2) · Germany (2) · Japan (2) · Kenya (2) · South Korea (2) · Canada (1) · France (1) · Puerto Rico (1) · The Gambia (1) · United Kingdom (1)
Kai Chu (2) · Myoung-don Oh, M.D. (2) · Anthony Scott, MD, PhD (1) · Christopher Bailey, Bsc, PhD (1) · Du Lin, Master (1) · Ed Clarke, MD PhD (1) · Eve Kennedy, PhD (1) · Evelyn Hatzenbichler, PhD (1) · Harry L Keyserling, MD (1)
PMID 30689507, PMID 15882530, PMID 17391816, PMID 18799552, PMID 19522655, PMID 20435707, PMID 22353593, PMID 23123106, PMID 23131206, PMID 23153437, PMID 23300160, PMID 23535358, PMID 23967126, PMID 24176494, PMID 25741971, PMID 25913828, PMID 26143615, PMID 26668712, PMID 29132988, PMID 31056427, PMID 31843266, PMID 33545022, PMID 35690500, PMID 36116461, PMID 36882898, PMID 37389808, PMID 38360475, PMID 39384037, PMID 39883948
2009 (1), 2015 (1), 2019 (1)